Fiche société
Genentech, Inc.
Traitements, essais et publications liés.
Traitements7programmes
Essais5liés
Publications7liées
SourceDBlocale
Traitements
7| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CevostamabThe study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN). | Lupus | Phase 1 | À vérifier | Spain | À vérifier |
| OCR SCThe purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV). | SEP | Phase 4 | Immunomodulation | United States, Puerto Rico | À vérifier |
| P-CD19CD20-ALLO1 CellsThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1. | Lupus | Phase 1 | Immunomodulation | United States | À vérifier |
| RimiducidThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1. | Lupus | Phase 1 | Immunomodulation | United States | À vérifier |
| OCR SCThe purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV). | SEP | Phase 4 | Immunomodulation | United States, Puerto Rico | À vérifier |
| CevostamabThe study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN). | Lupus | Phase 1 | À vérifier | Spain | À vérifier |
| P-CD19CD20-ALLO1 CellsThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1. | Lupus | Phase 1 | Immunomodulation | United States | À vérifier |
Essais cliniques
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 4 | NCT04377555 | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| P-CD19CD20-ALLO1 Cells | Lupus | Phase 1 | NCT06984341 | A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) | WITHDRAWN |
| Cevostamab | Lupus | Phase 1 | NCT07629583 | To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | RECRUITING |
| OCR SC | SEP | Phase 4 | NCT07609719 | OSSIA — A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | RECRUITING |
Publications
7| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Rimiducid | Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. | Cancer gene therapy | ||
| Cevostamab | Atypical Lymphocytosis Induced by T Cell-Engaging Therapy in Patients With Hematological Malignancies. | International journal of laboratory hematology | ||
| Rimiducid | PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. | Nature communications | ||
| Rimiducid | GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial. | Nature medicine | ||
| Cevostamab | Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. | Oncology (Williston Park, N.Y.) | ||
| Cevostamab | FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. | Nature medicine | ||
| OCR SC | Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. | Neurology |